- Home
- FSFG vs DMAC Comparison
FSFG vs DMAC Comparison
Compare FSFG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSFG
- DMAC
- Stock Information
- Founded
- FSFG 2008
- DMAC 2000
- Country
- FSFG United States
- DMAC United States
- Employees
- FSFG N/A
- DMAC N/A
- Industry
- FSFG Savings Institutions
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- FSFG Finance
- DMAC Health Care
- Exchange
- FSFG Nasdaq
- DMAC Nasdaq
- Market Cap
- FSFG 165.5M
- DMAC 178.0M
- IPO Year
- FSFG 2008
- DMAC N/A
- Fundamental
- Price
- FSFG $26.05
- DMAC $3.76
- Analyst Decision
- FSFG Strong Buy
- DMAC Strong Buy
- Analyst Count
- FSFG 3
- DMAC 2
- Target Price
- FSFG $31.50
- DMAC $8.00
- AVG Volume (30 Days)
- FSFG 55.1K
- DMAC 307.4K
- Earning Date
- FSFG 07-24-2025
- DMAC 08-06-2025
- Dividend Yield
- FSFG 2.46%
- DMAC N/A
- EPS Growth
- FSFG 159.10
- DMAC N/A
- EPS
- FSFG 2.81
- DMAC N/A
- Revenue
- FSFG $75,839,000.00
- DMAC N/A
- Revenue This Year
- FSFG $0.06
- DMAC N/A
- Revenue Next Year
- FSFG $8.60
- DMAC N/A
- P/E Ratio
- FSFG $9.26
- DMAC N/A
- Revenue Growth
- FSFG N/A
- DMAC N/A
- 52 Week Low
- FSFG $17.75
- DMAC $2.80
- 52 Week High
- FSFG $30.94
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- FSFG 55.34
- DMAC 47.18
- Support Level
- FSFG $23.49
- DMAC $3.48
- Resistance Level
- FSFG $26.28
- DMAC $3.99
- Average True Range (ATR)
- FSFG 0.77
- DMAC 0.32
- MACD
- FSFG 0.17
- DMAC -0.00
- Stochastic Oscillator
- FSFG 81.00
- DMAC 41.01
About FSFG First Savings Financial Group Inc.
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.